Clinical Trial Search

Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…

Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants

Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s

Primary: The Number of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (METAVIR Score) as Determined by Liver Biopsy After 12 Weeks of Treatment — 3; 6; 2…

Primary: The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12. — -0.00190; -0.00257 nanogram/ millitre/…

Primary: Shear Wave Velocity, VTQ — 1.95 meters per second

Primary: the Safety Profile of CAP 1002; Any Subjects Experiencing Any Safety Related Events During or Post Intracoronary Delivery and During the Follow up Period. — 0; 1…

Primary: Percentage of Participants With IPF Symptoms — 88.0; 51.8; 49.4; 42.9 Percentage of participants

Primary: 6 Minute Walk Distance — -6.2; -15.3 meters

Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants

Primary: EGCG PK Level in Healthy Volunteers — NA; NA; NA; 861 nM

Primary: Liver Stiffness Measured by MRE — 3.07 kPa

Primary: Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants — -2.807; -3.068; -1.120 Percent change from baseline in ppFVC

Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)

Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa

Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL) — -191.89; -85.32 Milliliter/year

Primary: Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period — -17.9; 116.6; -90.3; 125.6 milliliter (mL) — p=0.6777

Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…

Primary: Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs) — 0.147; 0.249; 0.334; 0.395 Cumulative incidence probability

Primary: Left Atrial (LA) Remodeling Pre-ablation — 2; 31; 7; 0 participants — p=0.48

Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…

Primary: Collagen Deposition in LT — 34.866; 31.02; 30.8925; 29.4492 percent area

Primary: The Clinical Value Evaluation of FibroTouch for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B by Using Liver Pathology as the Gold…

Primary: Mean Change From Baseline in Liver Biopsy Immunohistochemical Marker of Hepatic Stellate Cell (HSC) Activation and Collagen Synthesis at Week 52 — 0.02065; 0.02819…

Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -93.3; -52.4 millilitre (mL)/year (yr) — p=0.0350

Primary: Mean Time to Hemostasis (TTH) — 1.9; 4.8 minutes — p=<0.001

Primary: Safety of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy. — 55; 55…

Primary: Proportion of Subjects Achieving Hemostatic Success — 98.3; 53.3; 98.0 percentage of success

Primary: Time to Oxygen Therapy Initiation — 27.5; NA Months

Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055